Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001051483 | SCV001215638 | benign | Gorlin syndrome | 2025-01-15 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002416388 | SCV002724573 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-11-08 | criteria provided, single submitter | clinical testing | The p.T36R variant (also known as c.107C>G), located in coding exon 1 of the PTCH1 gene, results from a C to G substitution at nucleotide position 107. The threonine at codon 36 is replaced by arginine, an amino acid with similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |
St. |
RCV004789383 | SCV005402261 | uncertain significance | Basal cell nevus syndrome 1 | 2023-12-27 | criteria provided, single submitter | clinical testing | The PTCH1 c.107C>G (p.Thr36Arg) missense change is absent in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/). The in silico tool REVEL predicts a benign effect on protein function, but to our knowledge this prediction has not been confirmed by functional studies. To our knowledge, this variant has not been reported in individuals with nevoid basal cell carcinoma syndrome. In summary, the evidence currently available is insufficient to determine the clinical significance of this variant. It has therefore been classified as of uncertain significance. |